A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age

Since the last Italian cost-utility assessment of palivizumab in 2009, new data on the burden of respiratory syncytial virus (RSV) and an International Risk Scoring Tool (IRST) have become available. The objective of this study was to provide an up-to-date cost-utility assessment of palivizumab vers...

Descripción completa

Detalles Bibliográficos
Autores principales: Keary, Ian P., Ravasio, Roberto, Fullarton, John R., Manzoni, Paolo, Lanari, Marcello, Paes, Bosco A., Carbonell-Estrany, Xavier, Baraldi, Eugenio, Tarride, Jean-Éric, Rodgers-Gray, Barry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414677/
https://www.ncbi.nlm.nih.gov/pubmed/37561741
http://dx.doi.org/10.1371/journal.pone.0289828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414677/
https://www.ncbi.nlm.nih.gov/pubmed/37561741
http://dx.doi.org/10.1371/journal.pone.0289828

Ejemplares similares